To further probe the role of the circadian clock in treatment response, we generated CRISPR-Cas9 knockouts (KOs) of three key clock components—BMAL1, PER2, and NR1D1—in the T98G glioblastoma cell line. The gene discussed is NR1D1; the disease is glioblastoma.